Pfizer (PFE) FCF Margin (2009 - 2026)

Pfizer has disclosed FCF Margin across 18 years of filings, most recently posting 93.16% for Q1 2026.

• In Q1 2026, FCF Margin rose 934.0% year-over-year to 93.16%; the TTM figure through Mar 2026 stood at 38.76% (up 2774.0% YoY), while the FY2025 annual figure was 14.5%, down 10275.0% from the prior year.
• FCF Margin rose to 93.16% in Q1 2026, from 25.65% in the prior quarter.
• Over the last five years, FCF Margin for PFE reached as high as 911.99% in Q3 2024 and fell as low as 60.8% in Q3 2023.
• The 5-year median for FCF Margin is 26.74% (2022), against an average of 105.05%.
• Annual changes were most pronounced in 2024 — FCF Margin soared 75114 bps — and 2025, when it tumbled 73788 bps.
• A 5-year view of FCF Margin shows it stood at 81.5% in 2022, then jumped by 50 bps to 122.19% in 2023, then surged by 646 bps to 911.99% in 2024, then sank by 97 bps to 25.65% in 2025, then soared by 263 bps to 93.16% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 93.16%, 25.65%, and 174.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.